- Molecular NameCytarabine
- SynonymAra-C; Arabinocytidine; Arabinofuranosylcytosine; Arabinosylcytosine; AraC; Aracytidine; Aracytin; Aracytine; beta-Arabinosylcytosine; Beta-cytosine arabinoside; beta-D-Arabinosylcytosine; Citarabina [INN-Spanish]; Cytarabin; Cytarabina; cytarabine liposome injection; Cytarabinoside; Cytarabinum [INN-Latin]; Cytosine 1-beta-D-arabinofuranoside; Cytosine arabinofuranoside; Cytosine arabinose; Cytosine arabinoside; Cytosine beta-D-arabinoside; Cytosine-1-beta-D-arabinofuranoside; Cytosine-beta-arabinoside; Cytosine-beta-D-arabinofuranoside; Cytosine, beta-D-arabinoside
- Weight243.219
- Drugbank_IDDB00987
- ACS_NO147-94-4
- Show 3D model
- LogP (experiment)-2.18
- LogP (predicted, AB/LogP v2.0)-2.27
- pka4.3
- LogD (pH=7, predicted)-2.27
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-1.16
- LogSw (predicted, AB/LogsW2.0)9.15
- Sw (mg/ml) (predicted, ACD/Labs)16.76
- No.of HBond Donors5
- No.of HBond Acceptors8
- No.of Rotatable Bonds2
- TPSA128.61
- StatusFDA approved
- AdministrationInjectable (intravenous injection or infusion, intrathecal, or subcutaneously)
- PharmacologyA chemotherapy agent used mainly in the treatment of hematological malignancies such as acute myeloid leukemia (AML) and non-Hodgkin lymphoma.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability20.0
- Protein binding13.0
- Volume of distribution (VD)3.0 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmLiver
- Half life2.6 h
- ExcretionRenal
- Urinary Excretion11
- Clerance13 ml/min/kg
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A